Answers are grounded in this paper and cite their sources.
Single-cell analysis reveals a conserved 88-gene signature and lymph node origins of effector regulatory T cells across nine human epithelial cancers, highlighting precise immunotherapeutic targets.
CD4 + CD25 + FOXP3 + regulatory T cells (Treg) are highly activated in tumors and promote disease progression. Specific, universal targeting of these effector Treg cells is limited by the lack of a conserved signature across human cancers and information on their origin. Here we combine analysis of single-cell RNA-sequencing datasets with spectral flow cytometry and identify a core signature of 88 genes consistently upregulated in intratumoral Treg cells among 9 epithelial cancers. We describe 4 Treg cell subsets – CCR7 + quiescent, CCR8 + effector, CD161 + and intermediate, with distinct tissue distribution, function, differentiation trajectories and molecular drivers. By single-cell T cell receptor sequencing, we observe that protumoral, effector CCR8 + Treg cells exhibit little clonal relationship with other Treg cell subsets inside tumors, but are clonally related to Treg cells in tumor-draining lymph nodes, as well as conventional T cells in tumors. This resource provides insights for development and fine-tuning of CCR8 + Treg cell-targeting therapies in cancer.
No takes yet. Share an insight, caveat, or question.
Swatler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: